[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361557-105":59,"doc-detail-361557-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","folfox-based-transarterial-infusion-chemotherapy-for-unresectable-colorectal-cancer-protocol-of-an-open-label-multicentre-randomised-controlled-phase-ii-trial","FOLFOX-based transarterial infusion chemotherapy for unresectable colorectal cancer - protocol of an open-label, multicentre, randomised, controlled, phase II trial","","Colorectal cancer remains a leading cause of incidence and cancer-related mortality worldwide, and intravenous chemotherapy (IVC) often shows limited intratumoural drug accumulation. The protocol evaluates whether sequential IVC after intensive transarterial infusion chemotherapy (TAIC) improves outcomes versus IVC alone for unresectable colorectal cancer (uCRC). This prospective multicentre randomised open-label phase II trial enrolls 50 microsatellite stable/proficient mismatch repair patients, using FOLFOX-based TAIC plus sequential IVC compared with IVC-only. Primary endpoint is objective response rate.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/folfox-based-transarterial-infusion-chemotherapy-for-unresectable-colorectal-cancer-protocol-of-an-open-label-multicentre-randomised-controlled-phase-ii-trial/361557/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/folfox-based-transarterial-infusion-chemotherapy-for-unresectable-colorectal-cancer-protocol-of-an-open-label-multicentre-randomised-controlled-phase-ii-trial/361557.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What clinical question does this phase II trial address for unresectable colorectal cancer?","Question",{"text":113,"@type":114},"It tests whether sequential IVC given after intensive TAIC provides better clinical efficacy than IVC alone for unresectable colorectal cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How are patients assigned and what treatments do the two study arms receive?",{"text":118,"@type":114},"Fifty eligible patients are randomised to an IVC group or a TAIC group. The IVC group receives FOLFOX-based IVC every 2 weeks for 8 weeks, while the TAIC group receives FOLFOX-based TAIC at week 0 and week 4 followed by FOLFOX-based IVC at week 2 and week 6.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the primary endpoint and when is the trial scheduled to run?",{"text":122,"@type":114},"The primary endpoint is the objective response rate. The trial is scheduled to start on 10 January 2026 and complete follow-up on 31 December 2027.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},361557,1790197358,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":19,"preview_urls":145},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Open access Protocol  \n FOLFOX-based transarterial infusion  \nchemotherapy for unresectable colorectal cancer: protocol of an open-label, multicentre, randomised, controlled, phase II trial  \nJunpeng Wang  ,1 Yan Sun,1 Longchang Chen,1 Zheng Wang,1 Kaixuan Li,1 Ying Guo,1 Li Yao,2 Liuxin Duan,1 Quanda Liu1  \nTo cite: Wang J, Sun Y, Chen L, et al. FOLFOXbased transarterial infusion chemotherapy for unresectable colorectal cancer: protocol of an open-label, multicentre, randomised, controlled, phase II trial. BMJ Open  \n2026;16:e119746 . doi:10 . 1136/ bmjopen-2026-119746  \n► Prepublication history for this paper is available online. To view these files, please visit the journal online ([https://doi](https://doi). org/10 . 1136/bmjopen-2026- 119746) .  \nJW, YS and LC contributed equally.  \nReceived 16 March 2026 Accepted 17 August 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Department of General Surgery, Guanganmen Hospital, Beijing, China  \n2Department of Colorectal Surgery, China-Japan Friendship Hospital, Beijing, China  \nCorrespondence to  \nDr Quanda Liu; [quandaliu@163.com](quandaliu@163.com)  \nABSTRACT  \nIntroduction Colorectal cancer (CRC) is the third leading cause of new cancer cases and the second leading cause of cancer-related deaths worldwide. Current therapeutic modalities for CRC include surgical resection, intravenous chemotherapy (IVC), radiotherapy, immunotherapy, targeted therapy and their combinations. As a mainstream systemic treatment for CRC, IVC leads to widespread drug distribution but relatively low intratumoural  \ndrug accumulation. Compared with IVC, transarterial infusion chemotherapy (TAIC) involves selective arterial catheterisation to deliver chemotherapeutic agents directly to the tumour feeding vessels. Hepatic tumours receive their blood supply predominantly through branches of the hepatic artery. Hepatic artery infusion chemotherapy (HAIC) yields significantly superior outcomes compared with IVC and is currently widely employed for the treatment of primary and secondary hepatic malignancies. HAIC in combination with IVC can offer long-term durable disease control in the clinical treatment of liver cancer compared with IVC. CRC is also predominantly grown through angiogenesis. Therefore, we raise the question whether sequential IVC administered after intensive TAIC achieves better clinical efficacy than IVC alone for the treatment ofunresectable CRC (uCRC) . However, no prospective clinical trials have been conducted to compare the efficacy of these two strategies. This prospective study was therefore designed to fill this clinical knowledge gap.  \nMethods and analysis This is a prospective, multicentre, randomised, open‐label clinical trial. The uCRC is defined as inability to achieve an R0 resection owing to locally advanced CRC with clinical T4 disease confirmed by MRI or CT and/or synchronous liver metastases. This study only includes microsatellite stable or proficient mismatch repair uCRC. A total of 50 eligible patients  \nwill be randomly assigned to either the IVC group or the TAIC group. Patients in the IVC group will receive FOLFOX (fluorouracil, leucovorin, oxaliplatin)-based IVC every 2 weeks for a total duration of 8 weeks. Patients in the TAIC group will receive FOLFOX-based TAIC at week 0 and week 4 and receive FOLFOX-based IVC at week 2 and week 6. For patients with colorectal liver metastases, cetuximab or bevacizumab will be administered according  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ This is a prospective, multicentre, randomised, open‐label clinical trial designed to compare the differences in efficacy between intensive transarterial infusion chemotherapy (TAIC), followed by sequential intravenous chemotherapy (IVC) and IVC alone in the treatment of unresectable colorectal cancer (uCRC) .  \n⇒ Preliminary study yielded promising outcomes, supporting TAIC ","cbCaiufB2wkNFa23","https://ap.wps.com/l/cbCaiufB2wkNFa23","pdf",487103,"English","# Introduction\n## Trial rationale and clinical knowledge gap\n# Methods and analysis\n## Eligibility criteria and treatment regimens\n## Endpoints, schedule, and enrollment status\n# Strengths and limitations of the study\n## Design considerations and sample size\n# Ethics and dissemination\n## Approvals, trial registration, and analysis plan","[{\"question\":\"What clinical question does this phase II trial address for unresectable colorectal cancer?\",\"answer\":\"It tests whether sequential IVC given after intensive TAIC provides better clinical efficacy than IVC alone for unresectable colorectal cancer.\"},{\"question\":\"How are patients assigned and what treatments do the two study arms receive?\",\"answer\":\"Fifty eligible patients are randomised to an IVC group or a TAIC group. The IVC group receives FOLFOX-based IVC every 2 weeks for 8 weeks, while the TAIC group receives FOLFOX-based TAIC at week 0 and week 4 followed by FOLFOX-based IVC at week 2 and week 6.\"},{\"question\":\"What is the primary endpoint and when is the trial scheduled to run?\",\"answer\":\"The primary endpoint is the objective response rate. The trial is scheduled to start on 10 January 2026 and complete follow-up on 31 December 2027.\"}]","FOLFOX-based transarterial infusion chemotherapy for unresectable colorectal cancer - protocol of an open-label, multicentre, randomised, controlled, phase II trial | PDF",1790144826,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98adff6fdfd3065359fe430d1972a441.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d355fe7bf8342e80d15516758de33950.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/607d04f152dc0b6d3e028cd339ad9b06.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e856063b12fc07478456f304c30bbb4.webp",980,1306]